← Back to Screener
Nephros Inc. (NEPH)
Price$3.42
Value ScoreC
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-37.84%
Price vs S&P 500 (4W)-2.83%
VGM Score45.31
Market Capitalization$37.13M
P/E Ratio (Annual)31.10x
All Metrics
P/CF (Annual)22.57x
Book Value / Share (Quarterly)$0.99
P/TBV (Annual)5.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.48%
Cash Flow / Share (Quarterly)$-0.03
Price vs S&P 500 (YTD)-38.08%
Gross Margin (TTM)59.95%
Net Profit Margin (TTM)4.06%
EPS (TTM)$0.07
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$0.07
Revenue Growth (5Y)17.03%
EPS (Annual)$0.11
ROI (Annual)11.69%
Gross Margin (Annual)61.87%
Net Profit Margin (5Y Avg)-23.67%
Cash / Share (Quarterly)$0.37
P/E Basic Excl Extra (TTM)47.85x
Revenue Growth QoQ (YoY)6.87%
P/E Normalized (Annual)31.10x
ROA (Last FY)8.75%
Revenue Growth TTM (YoY)23.25%
EBITD / Share (TTM)$0.08
ROE (5Y Avg)-34.69%
Operating Margin (TTM)3.54%
Cash Flow / Share (Annual)$0.15
P/B Ratio3.47x
P/B Ratio (Quarterly)2.96x
Net Income / Employee (Annual)$33,200
EV / Revenue (TTM)1.73x
Net Interest Coverage (TTM)-427.00x
ROA (TTM)5.86%
EPS Growth QoQ (YoY)-75.86%
EV / EBITDA (TTM)39.48x
EPS Incl Extra (Annual)$0.11
Current Ratio (Annual)4.06x
Quick Ratio (Quarterly)2.98x
3-Month Avg Trading Volume0.04M
52-Week Price Return0.59%
EV / Free Cash Flow (Annual)20.14x
P/E Incl Extra (TTM)47.85x
Revenue / Employee (TTM)$531,200
Tangible BV / Share (Quarterly)$0.94
P/S Ratio (Annual)1.98x
Asset Turnover (Annual)1.38x
52-Week High$6.42
Operating Margin (5Y Avg)-15.13%
EPS Excl Extra (Annual)$0.11
CapEx CAGR (5Y)40.63%
Tangible BV CAGR (5Y)-3.04%
26-Week Price Return-29.92%
Quick Ratio (Annual)2.82x
13-Week Price Return-12.08%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.55x
Enterprise Value$33.13M
Revenue / Share Growth (5Y)12.69%
Asset Turnover (TTM)1.45x
Book Value / Share Growth (5Y)-5.45%
Revenue / Employee (Annual)$521,900
Inventory Turnover (Annual)2.45x
Pretax Margin (Annual)6.42%
Cash / Share (Annual)$0.51
3-Month Return Std Dev90.25%
Gross Margin (5Y Avg)56.99%
Net Income / Employee (TTM)$21,600
ROE (Last FY)11.70%
Net Interest Coverage (Annual)-95.00x
EPS Basic Excl Extra (Annual)$0.11
P/FCF (TTM)22.57x
Receivables Turnover (TTM)6.17x
EV / Free Cash Flow (TTM)21.08x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.07
Receivables Turnover (Annual)8.96x
ROI (TTM)7.65%
P/S Ratio (TTM)1.94x
Pretax Margin (5Y Avg)-14.82%
Revenue / Share (Annual)$1.71
Tangible BV / Share (Annual)$0.91
Forward P/E55.12x
Price vs S&P 500 (52W)-23.78%
P/E Ratio (TTM)47.85x
EPS Growth TTM (YoY)-5.36%
Year-to-Date Return-29.92%
5-Day Price Return-7.32%
EPS Normalized (Annual)$0.11
ROA (5Y Avg)-18.85%
Net Profit Margin (Annual)6.35%
Month-to-Date Return-6.56%
Cash Flow / Share (TTM)$-0.14
EBITD / Share (Annual)$0.12
Operating Margin (Annual)6.10%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)24.35x
ROI (5Y Avg)-34.10%
P/E Excl Extra (TTM)47.85x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.07
P/TBV (Quarterly)3.10x
P/B Ratio (Annual)5.08x
Inventory Turnover (TTM)2.75x
Pretax Margin (TTM)4.12%
Book Value / Share (Annual)$0.96
Price vs S&P 500 (13W)-20.34%
Beta1.52x
P/FCF (Annual)22.57x
Revenue / Share (TTM)$1.74
ROE (TTM)7.66%
52-Week Low$2.66
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.01est. 0.01
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NEPHNephros Inc. | C | C | D | $3.42 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Nephros Inc is a commercial-stage company developing high-performance water solutions for medical and commercial markets. The medical segment focuses on water filtration, pathogen detection, and next-generation hemodiafiltration systems for renal disease patients, while the commercial segment manufactures water filters that improve taste and reduce odor, biofilm, and equipment fouling. Revenue is primarily generated through product sales.